Skip to Content

Daunorubicin Disease Interactions

There are 5 disease interactions with daunorubicin:

Major

Daunorubicin (applies to daunorubicin) congestive heart failure

Major Potential Hazard, High plausibility.

Daunorubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment. The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2. An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.

References

  1. Ferrans VJ "Overview of cardiac pathology in relation to anthracycline cardiotoxicity." Cancer Treat Rep 62 (1978): 955-61
  2. Al-Ismail SA, Parry DH, Whittaker JA "Anthracycline cardiotoxicity and acute myelogenous leukaemia." Br Med J 1 (1977): 815
  3. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases." Am J Med 62 (1977): 200-8
  4. Harrison DT, Sanders LA "Letter: Pericarditis in a case of early daunorubicin cardiomyopathy." Ann Intern Med 85 (1976): 339-41
  5. Ainger LE, Bushore J, Johnson WW, Ito J "Daunomycin: a cardiotoxic agent." J Natl Med Assoc 63 (1971): 261-7
  6. Malhotra OP, Talwar KK, Chopra P, Kumar R "Erythroleukaemia and daunorubicin-induced cardiotoxicity in a young boy." Br J Clin Pract 44 (1990): 633-4
  7. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES "Cardiac ultrastructural changes induced by daunorubicin therapy." Cancer 32 (1973): 771-88
  8. Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E "Anthracycline induced myocardial damage. An analysis of 16 autopsy cases." Pathol Res Pract 181 (1986): 434-41
  9. Von Hoff DD, Layard M "Risk factors for development of daunorubicin cardiotoxicity." Cancer Treat Rep 65 Suppl 4 (1981): 19-23
  10. "Daunorubicin and the heart." Br Med J 4 (1974): 431-2
  11. Mhatre R, Herman E, Huidobro A, Waravdekar V "The possible relationship between metabolism and cardiac toxicity of duanomycin and related compounds." J Pharmacol Exp Ther 178 (1971): 216-22
View all 11 references
Major

Daunorubicin (applies to daunorubicin) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Daunorubicin can induce severe myelosuppression at therapeutic doses. The use of daunorubicin may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.
  2. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Daunorubicin (applies to daunorubicin) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Bleeding, Fever

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of the drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

References

  1. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Moderate

Daunorubicin (applies to daunorubicin) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes. Further metabolism via reduction and conjugation has been demonstrated. Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion. Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function. Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.

References

  1. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Moderate

Daunorubicin (applies to daunorubicin) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Approximately 25% of daunorubicin is eliminated in an active form in the urine. Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin. Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function. Clinical evaluation of renal function prior to each course of treatment is recommended.

References

  1. Morino N, Nojima Y, Mimura T, Hamasai K, Nakamoto T, Hirai H, Arai M, Matsuya S, Yazaki Y "Nephrotic syndrome developed in a patient with acute promyelocytic leukemia treated with daunomycin." Nephron 70 (1995): 374-5
  2. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  3. Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ "Doxorubicin hydrochloride-associated renal failure." Arch Intern Med 137 (1977): 385-8
  4. Thomson M, de Arriba G, Ordi J, Oliva H, Hernando L "Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome." Nephron 51 (1989): 261-4
View all 4 references

Daunorubicin drug interactions

There are 429 drug interactions with daunorubicin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.